Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use

Yasuo Suzukia Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Tokyo, Japan

Tomohiro Hiroseb Atopy (Allergy) Research Center, Juntendo University School of Medicine, Tokyo, Japan;c Immunology and Inflammation Medical Affairs, Pfizer Innovative Health, Pfizer Japan Inc, Tokyo, JapanCorrespondence[email protected]

Noriko Sugiyamad Clinical Statistics, Biometrics and Data Management, Pfizer R&D Japan, Tokyo, Japan

Kazuto Nomurae Post-Marketing Study Strategy and Management, Development Japan, Pfizer R&D Japan, Tokyo, Japan

Eduardo Campos-Albertoc Immunology and Inflammation Medical Affairs, Pfizer Innovative Health, Pfizer Japan Inc, Tokyo, Japan

Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date